Advertisement
SAN FRANCISCO, Nov. 15, 2018 /PRNewswire-PRWeb/ -- Through its Microbiome Grant Initiative, uBiome, the leader in microbial genomics, has awarded microbiome research support in study design, planning, sample collection, and analysis to a team of UCLA Department of Urology researchers led by Dr. William Aronson, MD, to conduct a randomized controlled trial to test the effects on the microbiome of a low-fat diet supplemented with fish oil in patients diagnosed with localized prostate cancer.
The goal of the study is to determine the effects of a low-fat diet supplemented with fish oil on the gut microbiota of men with prostate cancer after a three and six-month intervention. The patients will use uBiome's patented kits to sample their microbiome in the hopes of developing new potential cancer management strategies using a low-fat diet and fish oil supplements.
Dr. Susanne Henning, PhD, director of the Aronson Lab and an expert in nutrition and dietary interventions in cancer prevention, said, "Prostate cancer is a leading cause of cancer death among men in the United States, and there is an increasing need to develop strategies to slow its progression. We have found in previous studies that a low-fat diet supplemented with fish oil led to improved cellular markers of cancer cell proliferation, and we are interested in how this intervention alters the microbiota in prostate cancer patients."
Dr. William Aronson, MD, is a professor in the UCLA Department of Urology, Chief of Urology at the Olive View- UCLA Medical Center, and Director of Urologic Oncology at the Wadsworth Veterans Affairs Medical Center. Patients for this study are recruited from UCLA's Active Surveillance for Cancer of the Prostate Program.
"UCLA is a world-class research institution and we are proud to support this investigation by this incredible team," said Jessica Richman, PhD, co-founder and CEO of uBiome. "This study has the potential to lead to exciting new discoveries regarding the interaction of the microbiome, diet, and cancer progression."
Through its Microbiome Grant Initiative, uBiome has awarded millions of dollars in research support to hundreds of investigators around the world at renowned academic institutions and not-for-profit research organizations, including Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney. Awards include patented microbiome sequencing kits, as well as research support in study design, planning, sample collection, and analysis. To learn more about our award process or to submit a grant proposal, visit https://ubiome.com/microbiome-grant-initiative/. _____ About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
SOURCE Ubiome
Advertisement
The goal of the study is to determine the effects of a low-fat diet supplemented with fish oil on the gut microbiota of men with prostate cancer after a three and six-month intervention. The patients will use uBiome's patented kits to sample their microbiome in the hopes of developing new potential cancer management strategies using a low-fat diet and fish oil supplements.
Dr. Susanne Henning, PhD, director of the Aronson Lab and an expert in nutrition and dietary interventions in cancer prevention, said, "Prostate cancer is a leading cause of cancer death among men in the United States, and there is an increasing need to develop strategies to slow its progression. We have found in previous studies that a low-fat diet supplemented with fish oil led to improved cellular markers of cancer cell proliferation, and we are interested in how this intervention alters the microbiota in prostate cancer patients."
Dr. William Aronson, MD, is a professor in the UCLA Department of Urology, Chief of Urology at the Olive View- UCLA Medical Center, and Director of Urologic Oncology at the Wadsworth Veterans Affairs Medical Center. Patients for this study are recruited from UCLA's Active Surveillance for Cancer of the Prostate Program.
"UCLA is a world-class research institution and we are proud to support this investigation by this incredible team," said Jessica Richman, PhD, co-founder and CEO of uBiome. "This study has the potential to lead to exciting new discoveries regarding the interaction of the microbiome, diet, and cancer progression."
Through its Microbiome Grant Initiative, uBiome has awarded millions of dollars in research support to hundreds of investigators around the world at renowned academic institutions and not-for-profit research organizations, including Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney. Awards include patented microbiome sequencing kits, as well as research support in study design, planning, sample collection, and analysis. To learn more about our award process or to submit a grant proposal, visit https://ubiome.com/microbiome-grant-initiative/. _____ About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
SOURCE Ubiome
